[Skip to Content]
[Skip to Content Landing]
Article
December 18, 1991

The Cantekin Affair

Author Affiliations

From the Office of the Deputy Editor (West), JAMA, and the Institute for Health Policy Studies, University of California at San Francisco.

From the Office of the Deputy Editor (West), JAMA, and the Institute for Health Policy Studies, University of California at San Francisco.

JAMA. 1991;266(23):3333-3337. doi:10.1001/jama.1991.03470230091037
Abstract

In this issue of THE JOURNAL we publish an article by Cantekin and colleagues1 on the utility of amoxicillin trihydrate in otitis media: an article that was submitted to JAMA in 1987 and that had already become the center of a dispute about scientific misconduct. Why has it taken so long for this article to see the light of day? Why are we publishing it?

The Cantekin Case  Developments in the Cantekin case have been reported from time to time over the last 5 years in the lay and scientific press. Readers of JAMA will find much of it rehearsed by Cantekin et al2 in March 1990, and they will be able to get the flavor of this bitter dispute from the correspondence that followed.3,4 Two congressional hearings have touched on aspects of the case.5,6 In the briefest terms, in 1980, Dr Charles Bluestone set up

×